ADAM3B

Across TCGA pan-cancer cohorts, ADAM3B RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated ADAM3B data layer.

The strongest signal is observed in mesothelioma (MESO), where higher ADAM3B RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ADAM3B expression acts as an unfavorable survival marker, although some lineages such as LGG show a favorable association.

MESO, CESC, and LIHC are the cancer types where ADAM3B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	III,IV	0.278	0.617	<.001	144	view →
CESC	DFS	Tertile	II,III,IV	0.235	0.741	<.001	96	view →
LIHC	DFS	Tertile	II,III,IV	0.118	0.437	<.001	90	view →
KIRP	OS	Tertile	All	0.253	0.735	<.001	72	view →
COAD	OS	Tertile	IV	0.039	0.660	<.001	36	view →
STAD	DFS	Quartile	IV	0.097	0.409	.025	26	view →
READ	DFS	Tertile	IV	0.272	0.661	.004	24	view →
ACC	OS	Tertile	IV	0.327	0.633	.045	18	view →
HNSC	OS	Tertile	IV	0.205	0.523	.021	18	view →
LUAD	DFS	Tertile	IV	0.333	0.671	.048	18	view →
THCA	OS	Tertile	IV	0.720	1.000	.004	9	view →
KIRC	OS	Tertile	All	0.832	0.902	.033	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

ADAM3B–MESO (OS)

Open the MESO breakdown →